Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > GCAR

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 07, 2024 5:56pm

154 Views

Post# 35921557

RE:RE:RE:RE:RE:RE:RE:GCAR

And canadafan, I suggest that you listen to the conference call once again ... because ONCY is a LATE STAGE Biotech company that has addressed manufacturing over the course of 2023 and is now going into registration studies and regulatory approval. While early-stage biotechs focus on developing and testing their products, late-stage biotechs shift their focus to manufacturing, regulatory approval, and commercialization

<< Previous

Bullboard Posts

Next >>

Nextech CEO provides company update on Amazon deal and more